Spots Global Cancer Trial Database for immunogen
Every month we try and update this database with for immunogen cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer | NCT02606305 | Epithelial Ovar... Primary Periton... Fallopian Tube ... | Mirvetuximab so... Bevacizumab Carboplatin Pegylated Lipos... Pembrolizumab | 18 Years - | ImmunoGen, Inc. | |
A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer | NCT01237678 | Small Cell Lung... | IMGN901 Carboplatin and... | 18 Years - | ImmunoGen, Inc. | |
A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors | NCT01963715 | EGFR Positive S... | IMGN289 | 18 Years - | ImmunoGen, Inc. | |
A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors | NCT01963715 | EGFR Positive S... | IMGN289 | 18 Years - | ImmunoGen, Inc. | |
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer | NCT02631876 | Epithelial Ovar... Primary Periton... Fallopian Tube ... Ovarian Cancer | Mirvetuximab so... Paclitaxel Pegylated lipos... Topotecan | 18 Years - | ImmunoGen, Inc. |